IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.258
AS - Asia 3.042
EU - Europa 1.907
SA - Sud America 416
AF - Africa 48
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.682
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.157
SG - Singapore 1.543
IT - Italia 458
CN - Cina 457
RU - Federazione Russa 360
HK - Hong Kong 339
BR - Brasile 338
VN - Vietnam 240
IE - Irlanda 238
DE - Germania 205
FR - Francia 131
GB - Regno Unito 109
JP - Giappone 107
FI - Finlandia 95
BD - Bangladesh 94
UA - Ucraina 72
IN - India 68
CA - Canada 61
NL - Olanda 53
ID - Indonesia 39
SE - Svezia 37
KR - Corea 34
PL - Polonia 32
AR - Argentina 29
AT - Austria 28
ES - Italia 28
CO - Colombia 18
MX - Messico 18
PK - Pakistan 17
TR - Turchia 16
ZA - Sudafrica 16
CH - Svizzera 12
IQ - Iraq 12
EC - Ecuador 9
MA - Marocco 9
MY - Malesia 9
PH - Filippine 9
PY - Paraguay 9
CL - Cile 8
LT - Lituania 7
PT - Portogallo 7
UZ - Uzbekistan 7
AU - Australia 6
BE - Belgio 6
JM - Giamaica 6
RO - Romania 6
GR - Grecia 5
IR - Iran 5
KG - Kirghizistan 5
SA - Arabia Saudita 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
KE - Kenya 4
KZ - Kazakistan 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
EG - Egitto 3
EU - Europa 3
IL - Israele 3
LB - Libano 3
MN - Mongolia 3
NP - Nepal 3
PA - Panama 3
SI - Slovenia 3
TH - Thailandia 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
JO - Giordania 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BZ - Belize 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PS - Palestinian Territory 1
RE - Reunion 1
Totale 18.679
Salva come PNG Salva come JPEG
Città #
Wilmington 3.182
Houston 2.944
Woodbridge 1.607
Singapore 755
Fairfield 687
Ashburn 586
San Jose 440
Hong Kong 335
Seattle 332
Chandler 302
Council Bluffs 295
Cambridge 255
Dublin 219
Ann Arbor 191
Dallas 174
Beijing 163
The Dalles 158
Medford 152
Santa Clara 122
Tokyo 95
Rome 94
Dearborn 93
New York 88
Ho Chi Minh City 80
Los Angeles 79
Lawrence 72
Munich 67
Hanoi 63
Lauterbourg 63
Buffalo 58
Moscow 58
San Diego 54
Jacksonville 44
Helsinki 39
Milan 37
Redondo Beach 36
Lappeenranta 34
Nuremberg 33
Jakarta 31
São Paulo 30
London 29
Chennai 24
Toronto 22
Del Norte 21
Orem 21
Zhengzhou 21
Seoul 20
Salt Lake City 19
Menlo Park 18
Montreal 18
North Bergen 18
Boardman 17
Chicago 17
Perugia 17
Redwood City 16
Brooklyn 15
Frankfurt am Main 15
Warsaw 15
Colorado Springs 14
Vienna 14
Atlanta 13
Boston 13
Esslingen am Neckar 13
Hyderabad 13
Kraków 13
Shanghai 13
Denver 12
Johannesburg 12
Falls Church 10
Guangzhou 10
Manchester 10
Naples 10
Pune 9
Saint Petersburg 9
Turku 9
Amsterdam 8
Ankara 8
Charlotte 8
Da Nang 8
Haiphong 8
San Francisco 8
Stockholm 8
Turin 8
Asunción 7
Bologna 7
Engelhard 7
Phoenix 7
Poplar 7
Porto Alegre 7
Brussels 6
Columbus 6
Goiânia 6
Guiyang 6
Kilburn 6
Lahore 6
Mexico City 6
Montjovet 6
Norwalk 6
Rio de Janeiro 6
Zurich 6
Totale 14.859
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 533
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 443
Brodalumab for the treatment of psoriasis 437
Tildrakizumab for treating psoriasis 423
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 418
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 409
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 406
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 400
Tofacitinib for the treatment of psoriasis 398
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 397
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 393
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 369
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 367
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 367
A safety evaluation of guselkumab for the treatment of psoriasis 367
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 352
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 346
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 341
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 340
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 323
Photo-recall cutaneous reaction to gemcitabine 320
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 310
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 300
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 295
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 289
Pharmacotherapeutic management of psoriasis in adolescents and children 268
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 265
Skin immunity and its dysregulation in psoriasis 258
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 256
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 253
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 248
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 243
Successful treatment of psoriatic crumbly nails with ustekinumab 241
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 230
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 221
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 220
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 205
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 201
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 196
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 195
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 154
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 139
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 138
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 133
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 129
Italian guidelines in diagnosis and treatment of alopecia areata 129
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 122
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 121
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 120
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 119
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 111
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 111
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 110
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 107
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 107
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 107
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View 104
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 103
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 101
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 97
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 96
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 93
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 91
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 90
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 88
Effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a retrospective, real-world multicenter study with a focus on obese and multi-failure patients—IL PSO (Italian Landscape Psoriasis) 88
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 87
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 86
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 86
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 84
Quality of life and psychological impact in patients with atopic dermatitis 84
Linear psoriasis following the typical distribution of the sciatic nerve 83
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 82
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 81
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 81
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 79
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 79
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 78
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study–IL PSO (Italian Landscape Psoriasis) 77
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 77
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 76
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 76
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 74
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 73
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases 71
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 69
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 69
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 69
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 69
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 67
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 67
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 66
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study 66
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? 65
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 64
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 64
Eczematous liraglutide eruption managed by dupilumab: A case report 63
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 62
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 62
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 62
Totale 18.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.484
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.484
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202129 0 0 0 0 0 0 0 0 0 0 0 29
2021/2022861 46 69 81 14 31 35 140 34 60 52 73 226
2022/2023807 101 81 69 61 55 207 68 32 57 22 30 24
2023/2024565 33 6 15 16 45 80 93 51 3 40 120 63
2024/20252.543 101 412 246 266 49 279 108 119 238 198 315 212
2025/20264.458 293 158 578 254 359 152 627 526 552 510 369 80
Totale 19.370